Pfizer Securities Fraud Suit Must Stay In NJ: Judge
A federal judge on Tuesday rejected an attempt by Pfizer Inc. to move one of three securities fraud lawsuits over an Alzheimer's treatment drug to New York, leaving the class action...To view the full article, register now.
Already a subscriber? Click here to view full article